Last reviewed · How we verify
Statin, aspirin
Statin, aspirin is a Small molecule drug developed by Hillel Yaffe Medical Center. It is currently in Phase 1 development.
Statin and aspirin are used to prevent and treat various conditions, including Chronic Kidney Disease, Atherosclerotic Cardiovascular Disease, and Cardiovascular Disease, as indicated by ClinicalTrials.gov. Aspirin works as a small molecule cyclooxygenase inhibitor, according to ChEMBL, which is a class of drugs that inhibit the enzyme cyclooxygenase.
-
Baseline phase 1 → approval rate
+9.6pp
Industry-wide phase 1 drugs reach approval ~9.6% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).
| Regulator | Country | Likely year | Lag vs FDA |
|---|---|---|---|
| FDA | US | 2033–2036 | — |
| EMA | EU | 2034–2037 | +0.7 yr |
| MHRA | GB | 2034–2037 | +0.7 yr |
| Health Canada | CA | 2034–2038 | +0.9 yr |
| TGA | AU | 2034–2038 | +1.2 yr |
| PMDA | JP | 2034–2038 | +1.5 yr |
| NMPA | CN | 2035–2039 | +2.3 yr |
| MFDS | KR | 2034–2038 | +1.4 yr |
| CDSCO | IN | 2034–2039 | +1.8 yr |
| ANVISA | BR | 2035–2039 | +2.3 yr |
Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).
Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.
At a glance
| Generic name | Statin, aspirin |
|---|---|
| Sponsor | Hillel Yaffe Medical Center |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Optimal Antiplatelet and Lipid Therapy in ACS With DES: OPACT Trial (NA)
- Women's IschemiA TRial to Reduce Events In Non-ObstRuctive CAD (PHASE4)
- To Evaluate the Efficacy and Safety of Hearticelgram®-AMI in Patients With Acute Myocardial Infarction. (PHASE3)
- ASpirin Use and stAtin Strategy for Primary Prevention in Severe Coronary Calcium Score on Computed Tomography (PHASE4)
- Polypill and Colchicine for Risk Reduction in Atherosclerotic Cardiovascular Disease (PHASE3)
- A Polypill for Acute Coronary Syndrome (PHASE2)
- A EUROpean Randomized Study on Blood-thinners and Cholesterol-lowering Treatments to Prevent Future Vascular Events in People With Covert Brain Infarcts (CBI) (PHASE3)
- Efficacy and Safety Trials of Yangxinshi Tablets in the Treatment of Patients With Coronary Heart Disease Complicated by Cardiac Dysfunction (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Statin, aspirin CI brief — competitive landscape report
- Statin, aspirin updates RSS · CI watch RSS
- Hillel Yaffe Medical Center portfolio CI
Frequently asked questions about Statin, aspirin
What is Statin, aspirin?
Who makes Statin, aspirin?
What development phase is Statin, aspirin in?
Related
- Manufacturer: Hillel Yaffe Medical Center — full pipeline
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing